Biologic therapy in erythrodermic and pustular psoriasis

Journal of Drugs in Dermatology

Volumn 13, Issue 3, 2014, Pages 342-354

  Levin, Ethan C ^a   Debbaneh, Maya ^b   Koo, John ^a   Liao, Wilson ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIPSORIASIS AGENT; ETANERCEPT; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; USTEKINUMAB; DERMATOLOGICAL AGENT; IMMUNOLOGIC FACTOR;

ARTICLE; BIOLOGICAL THERAPY; CASE STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ERYTHRODERMIC PSORIASIS; HUMAN; MEDLINE; OPEN STUDY; PATIENT CARE; PUSTULAR PSORIASIS; SALVAGE THERAPY; UNSPECIFIED SIDE EFFECT; PATHOLOGY; PSORIASIS; SEVERITY OF ILLNESS INDEX;

BIOLOGICAL THERAPY; DERMATOLOGIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 84896342484     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Collins P, Rogers S. The efficacy of methotrexate in psoriasis - a review of 40 cases. Clin Exper Dermatol. 1992;17:257-60.
2. Mengesha YM, Bennett ML. Pustular skin disorders: diagnosis and treatment. Amer J Clinical Dermatol. 2002;3:389-400. (Pubitemid 34879432)
3. Moy RL, Kingston TP, Lowe NJ. Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis. Arch Dermatol.1985;121:1297-301. (Pubitemid 15248071)
4. Ozawa A, Ohkido M, Haruki Y et al. Treatments of generalized pustular psoriasis: a multicenter study in Japan. J Dermatol 1999;26:141-9. (Pubitemid 29166256)
5. Umezawa Y, Ozawa A, Kawasima T et al. Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity. Arch Dermatol Research 2003;295 Suppl 1:S43-54.
6. Management of erythrodermic psoriasis with low-dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO). Dermatology 1993;187 Suppl 1:30-7.
7. Geiger JM, Czarnetzki BM. Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies. Dermatologica 1988;176:182-90.
8. Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment. Journal of the European Academy of Dermatology and Venereology : JEADV 2000;14:382- 8.
9. Van Dooren-Greebe RJ, Kuijpers AL, Mulder J et al. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol. 1994;130:204-10. (Pubitemid 24204616)
10. Robinson A, Van Voorhees AS, Hsu S et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Amer Acad Dermatol. 2012;67:279-88.
11. Rosenbach M, Hsu S, Korman NJ et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Amer Acad Dermatol. 2010;62:655-62.
12. Esposito M, Mazzotta A, de Felice C et al. Treatment of erythrodermic psoriasis with etanercept. Br J Dermatol. 2006;155:156-9. (Pubitemid 43876409)
13. Poulalhon N, Begon E, Lebbe C et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol. 2007;156:329-36. (Pubitemid 46095962)
14. Torii H, Nakagawa H. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol. 2011;38:321-34.
15. .Viguier M, Pages C, Aubin F et al. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Br J Dermatol. 2012;167:417-23.
16. Viguier M, Guigue P, Pages C et al. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Annals Intern Med. 2010;153:66-7.
17. Wang TS, Tsai TF. Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: a case series. J Dermatol. 2011;38:1096-9.
18. Benoit S, Toksoy A, Brocker EB et al. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br J Dermatol. 2004;150:1009-12. (Pubitemid 38903538)
19. Chandran NS, Chong WS. A dramatic response to a single dose of infliximab as rescue therapy in acute generalized pustular psoriasis of von Zumbusch associated with a neutrophilic cholangitis. Australasian J Dermatol. 2010;51:29-31.
20. Lewis TG, Tuchinda C, Lim HW et al. Life-threatening pustular and erythrodermic psoriasis responding to infliximab. J Drugs Dermatol. 2006;5:546-8.
21. Newland MR, Weinstein A, Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Inter J Dermatol. 2002;41:449-52.
22. Routhouska SB, Sheth PB, Korman NJ. Long-term management of generalized pustular psoriasis with infliximab: case series. J Cutan Med Surg. 2008;12:184-8.
23. Schmick K, Grabbe J. Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab). Br J Dermatol. 2004;150:367. (Pubitemid 38352481)
24. Smith N, Harms KL, Hines AC et al. Acute treatment of generalized pustular psoriasis of von Zumbusch with single-dose infliximab. J American Acad Dermatol. 2013;68:e187-9.
25. Trent JT, Kerdel FA. Successful treatment of Von Zumbusch pustular psoriasis with infliximab. J Cutan Med Surg. 2004;8:224-8. (Pubitemid 41226447)
26. Vieira Serrao V, Martins A, Lopes MJ. Infliximab in recalcitrant generalized pustular arthropatic psoriasis. Eur J Dermatol. : EJD 2008;18:71-3. (Pubitemid 351158176)
27. Weisenseel P, Prinz JC. Sequential use of infliximab and etanercept in generalized pustular psoriasis. Cutis 2006;78:197-9. (Pubitemid 44484441)
28. Weishaupt C, Metze D, Luger TA et al. Treatment of pustular psoriasis with infliximab. Journal der Deutschen Dermatologischen Gesellschaft. J German Soc Dermatol. 2007;5:397-9.
29. Esposito M, Mazzotta A, Casciello C et al. Etanercept at different dosages in the treatment of generalized pustular psoriasis: a case series. Dermatology 2008;216:355-60. (Pubitemid 351630104)
30. Fiehn C, Andrassy K. Case number 29: hitting three with one strike: rapid improvement of psoriatic arthritis, psoriatic erythroderma, and secondary renal amyloidosis by treatment with infliximab (Remicade). Ann Rheum Diseas. 2004;63:232. (Pubitemid 38250662)
31. Lisby S, Gniadecki R. Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis. Acta Dermato-Venereol. 2004;84:247-8. (Pubitemid 38649414)
32. Rongioletti F, Borenstein M, Kirsner R et al. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. J Dermatol Treat. 2003;14:222-5. (Pubitemid 37474533)
33. Green MS, Prystowsky JH, Cohen SR et al. Infectious complications of erythrodermic psoriasis. J American Academy of Dermatol. 1996;34:911-4. (Pubitemid 26143880)
34. Takedai T, Yamamoto I, Tokeshi J. Acute generalized pustular psoriasis presenting with erythroderma associated with shock and acute renal failure. Hawaii medical journal 2003;62:278-81.
35. Sadeh JS, Rudikoff D, Gordon ML et al. Pustular and erythrodermic psoriasis complicated by acute respiratory distress syndrome. Archives Dermatol. 1997;133:747-50. (Pubitemid 27263709)
36. Kluger N, Bessis D, Guillot B et al. Acute respiratory distress syndrome complicating generalized pustular psoriasis (psoriasis-associated aseptic pneumonitis). Journal of the American Academy of Dermatology 2011;64:1154-8.
37. Abou-Samra T, Constantin JM, Amarger S et al. Generalized pustular psoriasis complicated by acute respiratory distress syndrome. Br J Dermatol. 2004;150:353-6. (Pubitemid 38352477)
38. Voigt GC, Kronthal HL, Crounse RG. Cardiac output in erythrodermic skin disease. American heart journal 1966;72:615-20.
39. Gordon K, Papp K, Poulin Y et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. Journal of the American Academy of Dermatology 2012;66:241-51.
40. Kimball AB, Papp KA, Wasfi Y et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol and Venereol 2012.
41. Menter A, Feldman SR, Weinstein GD et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J AmerAcad Dermatol. 2007;56:31 e1-15.
42. Tyring S, Gordon KB, Poulin Y et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Archives of dermatology. 2007;143:719-26. (Pubitemid 46955730)
43. Noiles K, Vender R. Biologic survival. J Drugs Dermatol. 2009;8:329-33.
44. Takahashi H, Tsuji H, Ishida-Yamamoto A et al. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J Dermatol. 2013;40:39-42.
45. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74. (Pubitemid 41443403)
46. Elewski BE. Infliximab for the treatment of severe pustular psoriasis. J Am Acad Dermatol. 2002;47:796-7. (Pubitemid 35239351)
47. Heikkila H, Ranki A, Cajanus S et al. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis. Arch Dermatol. 2005;141:1607-10. (Pubitemid 41815864)
48. Varma R, Cantrell W, Elmets C et al. Infliximab for the treatment of severe pustular psoriasis: 6 years later. J Eur Acad Dermatol Venereol 2008;22:1253-4.
49. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. New Engl J Med. 2003;348:601-8. (Pubitemid 36204954)
50. Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clinical gastroenterology and hepatology. the official clinical practice journal of the American Gastroenterological Association 2004;2:542-53.
51. Menter A, Gottlieb A, Feldman SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Amer Acad Dermatol. 2008;58:826-50. (Pubitemid 351509656)
52. Wee JS, Petrof G, Jackson K et al. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre. Br J Dermatol. 2012;167:411-6.
53. Edmonds EV, Morris SD, Short K et al. Pustular psoriasis of pregnancy treated with ciclosporin and high-dose prednisolone. Clinical and Exper Dermatol. 2005;30:709-10. (Pubitemid 41499835)
54. Finch TM, Tan CY. Pustular psoriasis exacerbated by pregnancy and controlled by cyclosporin A. Br J Dermatol. 2000;142:582-4. (Pubitemid 30159107)
55. Minkis K, Aksentijevich I, Goldbach-Mansky R et al. Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis mimicking infantile pustular psoriasis. Archives of dermatology 2012;148:747-52.
56. Reddy S, Jia S, Geoffrey R et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. The New England journal of medicine 2009;360:2438-44.
57. chnellbacher C, Ciocca G, Menendez R et al. Deficiency of Interleukin-1 Receptor Antagonist Responsive to Anakinra. Pediatric dermatology 2012.
58. Stenerson M, Dufendach K, Aksentijevich I et al. The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist. Arthritis and rheumatism 2011;63:4018-22.
59. Jesus AA, Osman M, Silva CA et al. A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil. Arthritis and rheumatism 2011;63:4007-17.
60. Marrakchi S, Guigue P, Renshaw BR et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. New Engl J Med. 2011;365:620-8.
61. Abrahams I, Mc CJ, Sanders SL. 101 cases of exfoliative dermatitis. Archives of dermatology 1963;87:96-101.
62. Nicolis GD, Helwig EB. Exfoliative dermatitis. A clinicopathologic study of 135 cases. Archives of dermatology 1973;108:788-97.
63. Wilson HT. Exfoliative dermatitis; its etiology and prognosis. AMA archives of dermatology and syphilology 1954;69:577-88.
64. Takahashi MD, Castro LG, Romiti R. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. Br J Dermatol. 2007;157:828-31. (Pubitemid 47389895)
65. O'Quinn RP, Miller JL. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases. Arch Dermatol. 2002;138:644-8.
66. Richetta AG, Maiani E, Carlomagno V et al. Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab. Dermatol Ther. 2009;22 Suppl 1:S16-8.
67. Fraga NA, Paim Mde F, Follador I et al. Refractory erythrodermic psoriasis in a child with an excellent outcome by using etanercept. An Bras Dermatol 2011;86:S144-7.
68. Santos-Juanes J, Coto-Segura P, Mas-Vidal A et al. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies. Br J Dermatol. 2010;162:1144-6.
69. Castineiras I, Fernandez-Diaz L, Juarez Y et al. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies. J Dermatol. 2012;39:730-1.
70. Buggiani G, D'Erme AM, Krysenka A et al. Efficacy of ustekinumab in sub-erythrodermic psoriasis: when TNF-blockers fail. Dermatologic therapy 2012;25:283-5.
71. Sheth N, Greenblatt DT, Acland K et al. Generalized pustular psoriasis of pregnancy treated with infliximab. Clinical Exper Dermatol. 2009;34:521-2.
72. Callen JP, Jackson JH. Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent. J Dermatol Treat. 2005;16:350-2. (Pubitemid 43170210)
73. Zangrilli A, Papoutsaki M, Talamonti M et al. Long-term efficacy of adalimumab in generalized pustular psoriasis. J Dermatol Treat. 2008;19:185-7. (Pubitemid 351883002)
74. Jordan J, Bieber T, Wilsmann-Theis D. Adalimumab: safe and successful in severe pustular psoriasis. J Euro Acad Dermatol Venereol. 2009;23:592-3.
75. Alvarez AC, Rodriguez-Nevado I, De Argila D et al. Recalcitrant pustular psoriasis successfully treated with adalimumab. Ped Dermatol. 2011;28:195-7.
76. Kimura U, Kinoshita A, Sekigawa I et al. Successful treatment with adalimumab in a patient with psoriatic arthritis and generalized pustular psoriasis. J Dermatol. 2012;39:1071-2.
77. Yawalkar N, Hunger RE. Successful treatment of recalcitrant palmoplantar pustular psoriasis with sequential use of infliximab and adalimumab. Dermatology 2009;218:79-83.
78. Pereira TM, Vieira AP, Fernandes JC et al. Anti-TNF-alpha therapy in childhood pustular psoriasis. Dermatology 2006;213:350-2. (Pubitemid 44837027)
79. Mikhail M, Weinberg JM, Smith BL. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus. Arch Dermatol. 2008;144:453-6. (Pubitemid 351581101)
80. Lo Schiavo A, Brancaccio G, Puca RV et al. Etanercept in the treatment of generalized annular pustular psoriasis. Ann Dermatol. 2012;24:233-4.
81. Floristan U, Feltes R, Ramirez P et al. Recalcitrant palmoplantar pustular psoriasis treated with etanercept. Ped Dermatol. 2011;28:349-50.
82. Andrulonis R, Ferris LK. Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol. 2012;11:1240.
83. Dauden E, Santiago-et-Sanchez-Mateos D, Sotomayor-Lopez E et al. Ustekinumab: effective in a patient with severe recalcitrant generalized pustular psoriasis. Br J Dermatol. 2010;163:1346-7.
84. Puig L, Morales-Munera CE, Lopez-Ferrer A et al. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review. Dermatology 2012;225:14-7.
85. Huffmeier U, Watzold M, Mohr J et al. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Brit J Dermatol. 2014;170:202-4.
86. Rossi-Semerano L, Piram M, Chiaverini C et al. First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra. Pediatrics 2013;132:e1043-7.